Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 403 of the 404 references it cites were found in a registry or an index.

Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text

Kolovou, Genovefa D., Watts, Gerald F., Mikhailidis, Dimitri P., Pérez-Martínez, Pablo, Mora, Samia, Bilianou, Helen, Panotopoulos, George, Katsiki, Niki, Ooi, Teik C., Lopez-Miranda, José, Tybjærg-Hansen, Anne, Tentolouris, Nicholas, Nordestgaard, Børge G. · 2019 · Current Vascular Pharmacology

Abstract

: Residual vascular risk exists despite the aggressive lowering of Low-Density Lipoprotein Cholesterol (LDL-C). A contributor to this residual risk may be elevated fasting, or non-fasting, levels of Triglyceride (TG)-rich lipoproteins. Therefore, there is a need to establish whethe a standardised Oral Fat Tolerance Test (OFTT) can improve atherosclerotic Cardiovascular (CV) Disease (ASCVD) risk prediction in addition to a fasting or non-fasting lipid profile. : An expert panel considered the role of postprandial hypertriglyceridaemia (as represented by an OFTT) in predicting ASCVD. The panel updated its 2011 statement by considering new studies and various patient categories. The recommendations are based on expert opinion since no strict endpoint trials have been performed. : Individuals with fasting TG concentration <1 mmol/L (89 mg/dL) commonly do not have an abnormal response to an OFTT. In contrast, those with fasting TG concentration ≥2 mmol/L (175 mg/dL) or nonfasting ≥2.3 mmol/L (200 mg/dL) will usually have an abnormal response. We recommend considering postprandial hypertriglyceridaemia testing when fasting TG concentrations and non-fasting TG concentrations are 1-2 mmol/L (89-175 mg/dL) and 1.3-2.3 mmol/L (115-200 mg/dL), respectively as an additional investigation for metabolic risk prediction along with other risk factors (obesity, current tobacco abuse, metabolic syndrome, hypertension, and diabetes mellitus). The panel proposes that an abnormal TG response to an OFTT (consisting of 75 g fat, 25 g carbohydrate and 10 g proteins) is >2.5 mmol/L (220 mg/dL). : Postprandial hypertriglyceridaemia is an emerging factor that may contribute to residual CV risk. This possibility requires further research. A standardised OFTT will allow comparisons between investigational studies. We acknowledge that the OFTT will be mainly used for research to further clarify the role of TG in relation to CV risk. For routine practice, there is a considerable support for the use of a single non-fasting sample.

Overview

Integrity signals

Registry

Crossref · 10.2174/1570161117666190507110519

Cites

403 of 403 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 404 references

Research works printed but not linked: 11

  1. Nordestgaard B.G.; Hilsted L.; Stender S.; Ugeskr Laeger 2009,171,1093
  2. Scartezini M.; Ferreira C.E.D.S.; Izar M.C.O.; Arq Bras Cardiol 2017,108,195-197
  3. Bradford-Hill A.; Proc R Soc Med 1965,58,295-300
  4. Lawler P.R.; Akinkuolie A.O.; Chu A.Y.; J Am Heart Assoc 2017,6
  5. Hegele R.A.; Ginsberg H.N.; Chapman M.J.; Lancet Diabetes Endocrinol 2014,2,655-666 · DOI · Paper page
  6. Varbo A.; Benn M.; Tybjærg-Hansen A.; Jørgensen A.B.; Frikke-Schmidt R.; Nordestgaard B.G.; J Am Coll Cardiol 2013,61,427-436 · DOI · Paper page
  7. Murphy M.C.; Isherwood S.G.; Sethi S.; Eur J Clin Nutr 1995,49,578-588
  8. Hegele R.; Ginsberg H.N.; Chapman M.J.; Lancet Diabetes Endocrinol 2014,2,655-666 · DOI · Paper page
  9. Aslam M.; Aggarwal S.; Sharma K.K.; Galav V.; Madhu S.V.; PLoS One 2016,11
  10. Alcala-Diaz J.F.; Delgado-Lista J.; Perez-Martinez P.; PLoS One 2014,9
  11. Yubero-Serrano E.M.; Delgado-Lista J.; Peña-Orihuela P.; Exp Mol Med 2013,45

Cited by

See all 67

Metadata

Authors
Kolovou, G. D., Watts, G. F., Mikhailidis, D. P., Pérez-Martínez, P., Mora, S., Bilianou, H., Panotopoulos, G., Katsiki, N., Ooi, T. C., Lopez-Miranda, J., Tybjærg-Hansen, A., Tentolouris, N., & Nordestgaard, B. G.
Affiliations
  • Onassis Cardiac Surgery Center (GR)
  • The University of Western Australia (AU)
  • The Royal Free Hospital (GB)
  • Lipid and Atherosclerosis Unit, IMIBIC/Reina Sofia University Hospital/University of Cordoba, and CIBER Fisiopatologia Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
  • Brigham and Women's Hospital (US)
  • Tzaneion General Hospital (GR)
  • Hygeia Hospital (GR)
  • AHEPA University Hospital (GR)
  • University of Ottawa (CA)
  • Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
  • First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece
  • University of Copenhagen (DK)
Corresponding author
Kolovou, Genovefa D.
Venue
Current Vascular Pharmacology
Published
2019-08-01
Volume
17
Issue
5
Pages
498-514
ISSN
1570-1611 (ISSN-L)
OpenAlex
W2944180110
Cited by
61
References
404
Citations by year
2026: 5 · 2025: 5 · 2024: 6 · 2023: 11 · 2022: 9 · 2021: 10 · 2020: 8 · 2019: 7
FWCI
8.12
Type
journal article
Language
en
Open access
closed
Locations
  • Current Vascular Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • UWA Profiles and Research Repository (UWA) (submittedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Funders
National Health Institutes (K24 HL136852, R01 HL134811, R01 DK112940)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
oral fat tolerance test, triglyceride-rich lipoproteins, residual cardiovascular risk, fasting triglycerides, metabolic risk assessment
MeSH terms
Blood Chemical Analysis, Cardiovascular Diseases, Humans, Predictive Value of Tests, Prognosis, Risk Factors, Triglycerides, Reproducibility of Results, Hypertriglyceridemia, Biomarkers, Up-Regulation, Risk Assessment, Postprandial Period, Consensus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. https://app.cochat.ai/papers/10.2174/1570161117666190507110519
The paper
Kolovou, G. D., Watts, G. F., Mikhailidis, D. P., Pérez-Martínez, P., Mora, S., Bilianou, H., Panotopoulos, G., Katsiki, N., Ooi, T. C., Lopez-Miranda, J., Tybjærg-Hansen, A., Tentolouris, N., & Nordestgaard, B. G. (2019). Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. Current Vascular Pharmacology. https://doi.org/10.2174/1570161117666190507110519

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.